Lloyds Pharmacy Uti Test, 2022 Emergency Management Summit And Training Sessions, Buxton Seawinds Okeechobee Funeral Home Obituaries, Valerie C Robinson Michael Schoeffling Wedding, Calcium Reacts With Oxygen To Form Calcium Oxide, Articles S

By their nature, forward-looking statements involve known and unknown risks and uncertainties and are subject to change because they relate to events and depend on circumstances that will occur in the future, including economic, regulatory, competitive and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Share Your Design Ideas, New JerseysMurphy Defends $10 Billion Rainy Day Fund as States Economy Slows, This Week in Crypto: Ukraine War, Marathon Digital, FTX. Sarah London is the Chief Executive Officer of Centene Corporation, a diversified healthcare enterprise providing a portfolio of government-sponsored healthcare programs focusing on under-insured and uninsured individuals to more than 26 million Americans. Neidorff turned it into a national player by competing aggressively for state Medicare contracts. Ms. London has spent her career at the intersection of health data, technology, and the transformation of value-based care for vulnerable Americans with the greatest needs. ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; Financial and other information about Centene is routinely posted and is accessible on Centene's investor relations website, https://investors.centene.com/. The Board and I are confident that she is the right visionary leader to increase value for our shareholders and author the next chapter of Centene's growth. Centene Corp. CNC (U.S.: NYSE) View All companies AT CLOSE 4:03 PM EST 01/05/23 $77.26 USD -2.20 -2.77% AFTER HOURS 6:24 PM EST 01/05/23 $76.26 -1.00 -1.29% AFTER HOURS Vol 211,456 Volume. She is on the Board of Directors at Centene Corp. Mr. Neidorff remains on a previously announced medical leave of absence from his position on the Board of the Company. Before joining Centene in 2020, Ms. London was a Partner at Optum Ventures, the venture capital arm of UnitedHealth Group. Prior to her appointment as CEO, Ms. London served as Vice Chairman of the Centene Board of Directors. View original content:https://www.prnewswire.com/news-releases/centene-appoints-sarah-london-as-chief-executive-officer-301508299.html, https://www.prnewswire.com/news-releases/centene-appoints-sarah-london-as-chief-executive-officer-301508299.html, Ukraine Latest: Saudi Generators Sent; Bakhmut Battles Continue, Pot vote has Oklahoma hungry to rake in green from Texas, How Ron DeSantis misreads Corporate America, Tesla recalls 3,470 Model Y vehicles over loose bolts, 3 big things in investing you might have missed this week. Published Mar 22, 2022 < 1 minute read. She started in data analytics at Optum and later was a partner in its venture capital arm. Glassdoor gives you an inside look at what it's like to work at Centene, including salaries, reviews, office photos, and more. These statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions. Forward-Looking StatementsAll statements, other than statements of current or historical fact, contained in this press release are forward-looking statements. Ms. London received a Bachelor of Arts in history and literature from Harvard College and a Master of Business Administration from the University of Chicago Booth School of Business. You may opt-out by. Get ready to start hearing the name "Centene" a lot more around Charlotte. 1. In a March 31 regulatory filing, Centene said its board of directors had approved a compensation package for new CEO Sarah London with an annual base salary of $1.4 million and a cash. .advancing integrated, value-based care models through the development and application of data-driven insights and technology. Londons promotion to CEO is effective immediately, Centene said. In her management role, Ms. London led the Company's technology and digital strategy in addition to running the Health Care Enterprises and Specialty divisions, Corporate Strategy, Quality Operations, Internal Audit, Compliance and Risk Management. Total Cash Compensationinformation is comprised of yearly Base Pay and Bonuses. JPMorgan Downgrades Centene to Neutral From Overweight, Adjusts Price Target to $90 Fro.. Analyst recommendations: BP, Centene, Experian, Intel, Walgreens.. CENTENE CORP Management's Discussion and Analysis of Financial Condition and Results Founded in 1984 and headquartered in St. Louis, Missouri, Centene Corporation is a diversified, multi-national healthcare enterprise that provides a portfolio of services to government sponsored and commercial healthcare programs, focusing on under-insured and uninsured individuals. Centene Centene has promoted Sarah London, the health insurance company's current board vice chair, to the job as Chief Executive Officer, succeeding the retiring Michael Neidorff, the. from 8 AM - 9 PM ET. Office phone: (773) 834-4302 Fax: (773) 702-6898 Office: BPSB 125C london@uchicago.edu. Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. Listen to free podcasts to get the info you need to solve business challenges! Centene ( NYSE: CNC) said it had appointed Sarah London to succeed Michael Neidorff as the Chief . Sarah's mailing address filed with the SEC is 7700, Forsyth Boulevard, Clayton, Saint Louis County, Missouri, 63105, United States . 1. ", "I am honored and humbled to have been selected as the next CEO of Centene and to work alongside extraordinary colleagues to provide quality healthcare to over 26 million Americans," said Ms. London. "I am delighted that the Board has appointed Sarah as CEO. Ms. London previously served as Vice President of Client Services & Operations with Humedica, a venture-backed healthcare data and analytics company acquired by Optum in 2013. Brent Layton, President and Chief Operating Officer of Centene, stated, "Sarah brings a tremendous skillset to the leadership of Centene Corporation, and I'm excited to partner closely with her as Centene begins our journey into the next era of our history. Spencer Stuart. Centene offers affordable and high-quality products to nearly 1 in 15 individuals across the nation, including Medicaid and Medicare members (including Medicare Prescription Drug Plans) as well as individuals and families served by the Health Insurance Marketplace, the TRICARE program, and individuals in correctional facilities. Her focus has been advancing integrated, value-based care models through the development and application of data-driven insights and technology. Her strategic thinking, fresh perspective and diverse experience make her the natural leader to harness the potential of Centene," said James Dallas, Acting Chairman of Centene. The Company takes a local approach with local brands and local teams to provide fully integrated, high-quality, and cost-effective services to government-sponsored and commercial healthcare programs, focusing on under-insured and uninsured individuals. Jan 3, 2023 09:43pm. And for those of us who are survivors of US health plans, top payer Centene, after 25 years of one man at the top, now has a new CEO, effective immediately. Sarah London. You should not place undue reliance on any forward-looking statements, as actual results may differ materially from projections, estimates, or other forward-looking statements due to a variety of important factors, variables and events including, but not limited to:our ability to accurately predict and effectively manage health benefits and other operating expenses and reserves, including fluctuations in medical utilization rates due to the impact of COVID-19; the risk that the election of new directors, changes in senior management and inability to retain key personnel may create uncertainty or negatively impact our ability to execute quickly and effectively;uncertainty as to the expected financial performance of the combined company following the recent completion of the Magellan Acquisition; the possibility that the expected synergies and value creation from the Magellan Acquisition or the WellCare Acquisition (or other acquired businesses) will not be realized, or will not be realized within the respective expected time periods; the risk that unexpected costs will be incurred in connection with the integration of the Magellan Acquisition or that the integration of Magellan Health will be more difficult or time consuming than expected, or similar risks from other acquisitions we may announce or complete from time to time; disruption from the integration of the Magellan Acquisition or from the integration of the WellCare Acquisition, or similar risks from other acquisitions we may announce or complete from time to time, including potential adverse reactions or changes to business relationships with customers, employees, suppliers or regulators, making it more difficult to maintain business and operational relationships; a downgrade of the credit rating of our indebtedness; competition; membership and revenue declines or unexpected trends; changes in healthcare practices, new technologies, and advances in medicine; increased healthcare costs; changes in economic, political or market conditions; changes in federal or state laws or regulations, including changes with respect to income tax reform or government healthcare programs as well as changes with respect to the Patient Protection and Affordable Care Act and the Health Care and Education Affordability Reconciliation Act (collectively referred to as the ACA) and any regulations enacted thereunder that may result from changing political conditions, the new administration or judicial actions; rate cuts or other payment reductions or delays by governmental payors and other risks and uncertainties affecting our government businesses; our ability to adequately price products; tax matters; disasters or major epidemics; changes in expected contract start dates; provider, state, federal, foreign and other contract changes and timing of regulatory approval of contracts; the expiration, suspension, or termination of our contracts with federal or state governments (including, but not limited to, Medicaid, Medicare, TRICARE or other customers); the difficulty of predicting the timing or outcome of legal or regulatory proceedings or matters, including, but not limited to, our ability to resolve claims and/or allegations made by states with regard to past practices, including at Envolve Pharmacy Solutions, Inc. (Envolve), as our pharmacy benefits manager (PBM) subsidiary, within the reserve estimate we have recorded and on other acceptable terms, or at all, or whether additional claims, reviews or investigations relating to our PBM business will be brought by states, the federal government or shareholder litigants, or government investigations; timing and extent of benefits from strategic value creation initiatives, including the possibility that these initiatives will not be successful, or will not be realized within the expected time periods; challenges to our contract awards; cyber-attacks or other privacy or data security incidents; the exertion of management's time and our resources, and other expenses incurred and business changes required in connection with complying with the undertakings in connection with any regulatory, governmental or third party consents or approvals for acquisitions; changes in expected closing dates, estimated purchase price and accretion for acquisitions; the risk that acquired businesses will not be integrated successfully;restrictions and limitations in connection with our indebtedness; our ability to maintain or achieve improvement in the Centers for Medicare and Medicaid Services (CMS) Star ratings and maintain or achieve improvement in other quality scores in each case that can impact revenue and future growth; availability of debt and equity financing, on terms that are favorable to us; inflation; foreign currency fluctuations and risks and uncertainties discussed in the reports that Centene has filed with the Securities and Exchange Commission.